North Shore Dispensary Launches in Duluth’s Lincoln Park Neighborhood
The north shore dispensary opens in Duluth’s Lincoln Park, expanding legal cannabis access in the region. This new dispensary supports Minnesota’s medical cannabis program by improving patient access. Local clinicians can now better guide patients on…
Cannabis Legalization Driving Increases in Marijuana Use Among Historically Marginalized US Adults
Cannabis use among historically marginalized adults has increased following legalization in the US. This shift reflects greater availability and reduced stigma but raises clinical concerns. Understanding cannabis use patterns in these populations is…
From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s Reckoning
Cannabis industry regulatory enforcement is intensifying as the FDA issues cease-and-desist letters to hemp beverage companies. These actions address unsubstantiated claims about cannabinoid products. Clinicians must navigate this evolving landscape to…
Tilray CEO Discusses US Cannabis Reclassification and Market Outlook
The US cannabis reclassification could ease federal restrictions and open new research opportunities. Tilray's CEO highlights potential market expansion tied to these regulatory changes. This shift may facilitate clinical evidence development and broader…
Tilray Surges 10%: Rescheduling Momentum Builds as Traders Await Confirmation
Federal cannabis rescheduling momentum is driving significant changes in the cannabis industry and clinical research landscape. This momentum is reflected in market movements such as Tilray's recent surge. Clinicians should monitor these developments as…
Cannabis Stocks Rise and Fall Amid Clinical Evidence and Rescheduling News
Cannabis stocks clinical evidence highlights the impact of federal rescheduling news on market volatility. This shift could expand clinical research opportunities and improve patient access. Clinicians should monitor these developments closely for safer…
Understanding the Clinical Implications of Marijuana Reclassification
The marijuana reclassification clinical implications are significant for research and clinical practice. Moving marijuana to Schedule III could ease regulatory barriers and improve access to cannabis-based therapies. Clinicians must still rely on…
Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
Tilray U S expansion is gaining momentum amid historic federal cannabis rescheduling efforts. This shift could enhance clinical research opportunities and improve patient access to standardized cannabis medicines. The regulatory changes may transform…
The US Moves Cannabis from Schedule I to Schedule III – StratCann
The cannabis federal rescheduling impacts clinical research by removing barriers to rigorous studies. This regulatory change enables better access to quality-controlled cannabis products. Patients and clinicians benefit from improved evidence and…
Congress Has The Votes To Pass Federal Marijuana Reform
Your pulmonologist’s DEA form just got a lot less complicated. Finally, the Schedule I paperwork goes where it belongs: into history. Via r/trees Further Reading Cannabis Policy WireSchedules of Controlled Substances: Temporary Placement of…
